Capricor Therapeutics (CAPR) Debt to Equity (2016 - 2024)
Capricor Therapeutics (CAPR) has 14 years of Debt to Equity data on record, last reported at $0.05 in Q3 2024.
- For Q3 2024, Debt to Equity rose 102.62% year-over-year to $0.05; the TTM value through Sep 2024 reached $0.05, up 102.62%, while the annual FY2023 figure was $0.15, 49.2% down from the prior year.
- Debt to Equity reached $0.05 in Q3 2024 per CAPR's latest filing, down from $0.29 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.24 in Q2 2023 and bottomed at -$1.89 in Q3 2023.
- Average Debt to Equity over 5 years is $0.12, with a median of $0.15 recorded in 2023.
- Peak YoY movement for Debt to Equity: surged 4900.78% in 2021, then plummeted 941.96% in 2023.
- A 5-year view of Debt to Equity shows it stood at $0.0 in 2020, then soared by 4900.78% to $0.13 in 2021, then skyrocketed by 131.99% to $0.29 in 2022, then crashed by 49.2% to $0.15 in 2023, then plummeted by 66.89% to $0.05 in 2024.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.05 in Q3 2024, $0.29 in Q2 2024, and $0.18 in Q1 2024.